#her2
Trastuzumab is the classic example: It works against HER2+ tumours, but cardiotoxicity limits it, because cardiomyocytes also express HER2.

What differs between the tumour and healthy cells is density, not identity.
November 18, 2026 at 6:49 PM
The @US_FDA approved the oral selective estrogen degrader giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred or progressed with endocrine therapy: buff.ly/EjdVsoI
FDA approves giredestrant
In combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
buff.ly
November 16, 2026 at 9:08 PM
The @fda.gov has approved giredestrant in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer.
FDA approves new oral treatment for patients with advanced breast cancer
The U.S. Food and Drug Administration (FDA) has approved giredestrant in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer based on results from the phase 3 evERA clinical trial, led by investigators at Dana-Farber Cancer Institute.
bit.ly
November 17, 2026 at 9:15 PM
The @fda.gov has approved pertuzumab-qcay, a biosimilar referencing pertuzumab, for combination use with trastuzumab in patients with HER2-positive breast cancer across 3 settings. #bcsm #oncology

Read more: www.onclive.com/view/pertuzu...
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer | OncLive
Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.
www.onclive.com
November 16, 2026 at 11:12 PM
#OLMA Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposi…

https://www.stocktitan.net/news/OLMA/olema-oncology-presents-preclinical-data-on-selective-kat6a-b309dkg5r3nk.html?utm_source=stocktitan-bluesky&utm_medium=social
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Olema Oncology (Nasdaq: OLMA) announced preclinical results for selective KAT6A protein degraders in estrogen receptor-positive, HER2-negative breast cancer models.All four compounds, OP-1 through OP-4, produced near-complete degradation of KAT6A with minimal effects on other targets. The compounds inhibited cancer cell proliferation, and activity was observed in models with both mutant and wild-type (nonmutated) ESR1. Used alone, the degraders caused tumor regression in T47D and slowed tumor growth in MCF7 and ST941. They were well tolerated across all groups in studies using implanted tumors.The compounds were absorbed after oral dosing in preclinical studies, which Olema said suggests the potential for once-daily dosing in humans. The findings are scheduled for a poster presentation on November 18, 2026, at the EORTC-NCI-AACR Symposium in Barcelona.
www.stocktitan.net
November 18, 2026 at 7:30 AM
A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation https://www.biorxiv.org/content/10.64898/2026.11.12.760175v1
November 14, 2026 at 1:45 AM
HER2 Human Epidermal Growth Factor Receptor 2 Antibody Market | WiseGuyReports www.wiseguyreports.com/reports/her2...
HER2 Human Epidermal Growth Factor Receptor 2 Antibody Market
HER2 Human Epidermal Growth Factor Receptor 2 Antibody Market is Estimated to Reach USD 14.5 Billion by 2035, Growing at a CAGR of 5.9% During 2026 - 2035
www.wiseguyreports.com
November 14, 2026 at 2:00 PM
HER2 emerges as a critical target for CAR T-cell therapy in various cancers due to its overexpression. Researchers highlight HER2's potential for solid tumor treatment, emphasizing its role in cancer stem cell renewal and tumor maintenance.

🔗 Source: https://pubmed.ncbi.nlm.nih.gov/43035167/
November 17, 2026 at 6:13 AM
WATCH 🎥: Tiffany A. Traina, MD, FASCO, of @mskcancercenter.bsky.social, discusses incorporating T-DXd and biomarkers into early-stage HER2-positive breast cancer treatment. #bcsm #oncology

Full video ➡️: www.onclive.com/view/dr-trai...
Dr Traina on Integrating T-DXd and Biomarkers Into Early-Stage HER2-Positive Breast Cancer Care | OncLive
Tiffany A. Traina, MD, FASCO, discusses incorporating T-DXd and biomarkers into early-stage HER2-positive breast cancer treatment.
www.onclive.com
November 12, 2026 at 2:23 AM
Duality/BioNTech: Phase 3 DYNASTY-Breast02 met its PFS primary endpoint for HER2 ADC trastuzumab pamirtecan (DB-1303/BNT323) vs chemo in 541 HR+/HER2-low metastatic breast cancer patients; the gain was modest, OS immature and ILD higher than in prior trials. https://inlightbio.com/news/?type=clin
November 14, 2026 at 12:36 PM
FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer

www.fda.gov/drugs/cancer...
FDA approves giredestrant
In combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
www.fda.gov
November 17, 2026 at 12:32 AM
DESTINY-Breast09 in Practice: A Risk-Adapted Approach to First-Line T-DXd Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer dailynews.ascopubs.org/do/destiny-b...
DESTINY-Breast09 in Practice: A Risk-Adapted Approach to First-Line T-DXd Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer
DESTINY-Breast09 established trastuzumab deruxtecan plus pertuzumab as an effective first-line regimen in HER2-positive metastatic breast cancer, but translating that benefit into everyday practice re...
dailynews.ascopubs.org
November 12, 2026 at 4:13 PM
📢 健保署近年開放新藥給付於荷爾蒙陰性的HER2弱陽性乳癌晚期患者;醫師指出,占總體乳癌約45%的荷爾蒙陽性HER2弱陽性病友,仍苦等健保接軌,呼籲儘速補齊晚期乳癌治療拼圖。
晚期HER2弱陽性治療拼圖 醫:45%乳癌苦盼健保接軌 | 生活 | 中央社 CNA
www.cna.com.tw
November 15, 2026 at 9:47 AM
#中央社即時新聞 生活醫藥 15:36

晚期HER2弱陽性治療拼圖 醫:45%乳癌苦盼健保接軌

(中央社記者陳婕翎台北15日電)健保署近年開放新藥給付於荷爾蒙陰性的HER2弱陽性乳癌晚期患者;醫師指出,占總體乳癌約45%的荷爾蒙陽性HER2弱陽性病友,仍苦等健保接軌,呼籲儘速補齊晚期乳癌治療拼圖。

https://www.cna.com.tw/news/ahel/202611150109.aspx

#新聞
晚期HER2弱陽性治療拼圖 醫:45%乳癌苦盼健保接軌 | 生活 | 中央社 CNA
健保署近年開放新藥給付於荷爾蒙陰性的HER2弱陽性乳癌晚期患者;醫師指出,占總體乳癌約45%的荷爾蒙陽性HER2弱陽性病友,仍苦等健保接軌,呼籲儘速補齊晚期乳癌治療拼圖。
www.cna.com.tw
November 15, 2026 at 8:45 AM
#NEWS: Our targeted therapy is approved in Japan as a first-line treatment option for people with HER2-mutant advanced NSCLC.

Lung cancer is the leading cause of cancer death in Japan. This approval is an important step forward for people facing HER2-driven lung cancer.

go.boehringer.com/E3zcB
November 16, 2026 at 7:26 AM
Meta-analysis of 8 RCTs (8367 patients) with HER2-positive breast cancer: pertuzumab-based regimens improved overall survival in advanced/metastatic disease (HR 0.71) but not significantly in neoadjuvant/adjuvant settings (HR 0.81, 95% CI 0.22-3.04); adverse events similar.
Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials
Meta-analysis, n = 8,367 · Breast Cancer Res Treat. Summary of the abstract on Y (askwhy.science).
askwhy.science
November 18, 2026 at 2:15 AM
Wilserdly, an oral estrogen receptor antagonist, is now approved in combination with everolimus for previously treated ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. www.empr.com/news/fda-app...
Wilserdly With Everolimus Approved for ESR1-Mutated Advanced Breast Cancer
Wilserdly (giredestrant), an oral estrogen receptor antagonist, is now approved in combination with everolimus for adults with previously treated ER-positive, HER2-negative, ESR1-mutated locally advan...
www.empr.com
November 17, 2026 at 10:02 PM
📢 New Companion Diagnostic Approval – our blood-based comprehensive genomic profiling (CGP) test is now FDA-approved to identify patients with ER-positive, HER2-negative, ESR1-mutated advanced #BreastCancer.

Read more: www.foundationmedicine.com/press-releas...
November 16, 2026 at 11:19 PM
A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation https://www.biorxiv.org/content/10.64898/2026.11.12.760175v1
November 14, 2026 at 1:45 AM